FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2568427609> ?p ?o ?g. }

• W2568427609 endingPage "S1240" @default.
• W2568427609 startingPage "S1239" @default.
• W2568427609 abstract "Patients with advanced non-small-cell lung cancer (NSCLC) whose tumors harbor activating mutations in the epidermal growth factor receptor (EGFR) gene, derive substantial clinical benefit from treatment with first and second-line EGFR tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, erlotinib and afatinib. However, their comparative effectiveness in this setting has not been evaluated, due to the paucity of randomized comparative clinical trials. We performed a comprehensive literature search in PUBMED, EMBASE, SCOPUS and ISI databases for randomized clinical trials evaluating either of the aforementioned EGFR-TKIs in first- and subsequent-lines treatment of EGFR-positive advanced NSCLC. All sensitizing mutations to EGFR-TKI inhibition were included in the current analysis. Patients with active brain metastases, with ECOG performance status of more than 2, as well as trials comparing the combination of EGFR-TKI with chemotherapy to chemotherapy alone were excluded. Comparative study outcomes included objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and rate of adverse events (AE). Cochrane guidelines were used for statistical analysis. 13 randomized trials incorporating 3,853 patients were eligible for the analysis. In the first-line setting, all EGFR TKIs showed improved outcomes with respect to ORR and PFS when compared to standard platinum-doublet chemotherapy. Comparative ORR rates for gefitinib, erlotinib and afatinib in first-line were 71.5%, 70.2% and 50.1% respectively. HRs for PFS were 0.40 (95% CI: 0.31- 0.50) for gefitinib, 0.25 (0.11-0.56) for erlotinib and 0.40 (0.28-0.57) for afatinib, all three with p<0.001. Respective HRs for OS were 0.89 (0.72-1.10) for Gefitinib, 0.91 (0.76-1.13) for erlotinib and 1.05 (0.88-1.25) for afatinib. No significant differences were detected regarding common AEs (rash, diarrhea) among the three agents. Evidence data for gefitinib were less heterogeneous than those for erlotinib and afatinib. When compared indirectly, gefitinib exhibited the more consistent results from a statistical point of view and erlotinib had the more favorable profile regarding PFS prolongation. These data challenge the current landscape of first and second generation EGFR-TKIs in EGFR mutant advanced NSCLC and especially those of the recently reported LUX-LUNG 7 trial." @default.
• W2568427609 created "2017-01-13" @default.
• W2568427609 creator A5015356197 @default.
• W2568427609 creator A5018145340 @default.
• W2568427609 creator A5034976961 @default.
• W2568427609 creator A5044610238 @default.
• W2568427609 creator A5053819122 @default.
• W2568427609 creator A5068401391 @default.
• W2568427609 creator A5083008045 @default.
• W2568427609 creator A5083540954 @default.
• W2568427609 creator A5090057211 @default.
• W2568427609 date "2017-01-01" @default.
• W2568427609 modified "2023-10-01" @default.
• W2568427609 title "P3.02b-081 Comparative Outcome Assessment of EGFR TKIs for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis" @default.
• W2568427609 doi "https://doi.org/10.1016/j.jtho.2016.11.1748" @default.
• W2568427609 hasPublicationYear "2017" @default.
• W2568427609 type Work @default.
• W2568427609 sameAs 2568427609 @default.
• W2568427609 citedByCount "0" @default.
• W2568427609 crossrefType "journal-article" @default.
• W2568427609 hasAuthorship W2568427609A5015356197 @default.
• W2568427609 hasAuthorship W2568427609A5018145340 @default.
• W2568427609 hasAuthorship W2568427609A5034976961 @default.
• W2568427609 hasAuthorship W2568427609A5044610238 @default.
• W2568427609 hasAuthorship W2568427609A5053819122 @default.
• W2568427609 hasAuthorship W2568427609A5068401391 @default.
• W2568427609 hasAuthorship W2568427609A5083008045 @default.
• W2568427609 hasAuthorship W2568427609A5083540954 @default.
• W2568427609 hasAuthorship W2568427609A5090057211 @default.
• W2568427609 hasBestOaLocation W25684276091 @default.
• W2568427609 hasConcept C121608353 @default.
• W2568427609 hasConcept C126322002 @default.
• W2568427609 hasConcept C143998085 @default.
• W2568427609 hasConcept C168563851 @default.
• W2568427609 hasConcept C2776256026 @default.
• W2568427609 hasConcept C2776694085 @default.
• W2568427609 hasConcept C2778087573 @default.
• W2568427609 hasConcept C2779438470 @default.
• W2568427609 hasConcept C2780258809 @default.
• W2568427609 hasConcept C2780580887 @default.
• W2568427609 hasConcept C2780586478 @default.
• W2568427609 hasConcept C2780739268 @default.
• W2568427609 hasConcept C2909325608 @default.
• W2568427609 hasConcept C535046627 @default.
• W2568427609 hasConcept C71924100 @default.
• W2568427609 hasConceptScore W2568427609C121608353 @default.
• W2568427609 hasConceptScore W2568427609C126322002 @default.
• W2568427609 hasConceptScore W2568427609C143998085 @default.
• W2568427609 hasConceptScore W2568427609C168563851 @default.
• W2568427609 hasConceptScore W2568427609C2776256026 @default.
• W2568427609 hasConceptScore W2568427609C2776694085 @default.
• W2568427609 hasConceptScore W2568427609C2778087573 @default.
• W2568427609 hasConceptScore W2568427609C2779438470 @default.
• W2568427609 hasConceptScore W2568427609C2780258809 @default.
• W2568427609 hasConceptScore W2568427609C2780580887 @default.
• W2568427609 hasConceptScore W2568427609C2780586478 @default.
• W2568427609 hasConceptScore W2568427609C2780739268 @default.
• W2568427609 hasConceptScore W2568427609C2909325608 @default.
• W2568427609 hasConceptScore W2568427609C535046627 @default.
• W2568427609 hasConceptScore W2568427609C71924100 @default.
• W2568427609 hasIssue "1" @default.
• W2568427609 hasLocation W25684276091 @default.
• W2568427609 hasOpenAccess W2568427609 @default.
• W2568427609 hasPrimaryLocation W25684276091 @default.
• W2568427609 hasRelatedWork W1480640671 @default.
• W2568427609 hasRelatedWork W2186047679 @default.
• W2568427609 hasRelatedWork W2542769082 @default.
• W2568427609 hasRelatedWork W2793959215 @default.
• W2568427609 hasRelatedWork W2888534976 @default.
• W2568427609 hasRelatedWork W3000070469 @default.
• W2568427609 hasRelatedWork W3175282903 @default.
• W2568427609 hasRelatedWork W4281690819 @default.
• W2568427609 hasRelatedWork W4285031963 @default.
• W2568427609 hasRelatedWork W4307234767 @default.
• W2568427609 hasVolume "12" @default.
• W2568427609 isParatext "false" @default.
• W2568427609 isRetracted "false" @default.
• W2568427609 magId "2568427609" @default.
• W2568427609 workType "article" @default.